|
1
|
Villy MC, Masliah-Planchon J, Melaabi S, Trabelsi Grati O, Girard E, Bataillon G, Vincent-Salomon A, Le Gall J, Golmard L, Stoppa-Lyonnet D, Bieche I, Colas C. Tumor BRCA testing can reveal a high tumor mutational burden related to POLE pathogenic variants. Gynecol Oncol Rep 2021; 37:100855. [PMID: 34541275 PMCID: PMC8435919 DOI: 10.1016/j.gore.2021.100855] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/13/2021] [Revised: 08/27/2021] [Accepted: 08/29/2021] [Indexed: 11/18/2022] Open
Abstract
Some gynecologic tumors harbor a POLE pathogenic variant, raising prognostic and therapeutic issues. Tumors harboring a POLE pathogenic variant exhibit multiple BRCA1/2 variants, reflecting the high tumor mutational burden. Tumor BRCA testing could be a way to detect tumors harboring a highly mutagenic POLE pathogenic variant.
Objective Tumors harboring a POLE pathogenic variant, associated with high tumor mutational burden, are good candidates for immunotherapy. However, POLE pathogenic variants are not currently screened in routine clinical practice. Can these tumors be identified by means of an already available test? Methods We describe seven tumors harboring a POLE pathogenic variant, among eight patients with tumors harboring multiple BRCA1/2 variants (from 4 to 20). All patients were managed at Institut Curie, Paris. Five patients were selected because of unexpected tumor BRCA testing results with multiple variants and another three patients were selected because of a POLE pathogenic variant detected by large tumor testing. We looked for other tumor variants by Next-Generation Sequencing in tumors harboring multiple BRCA1/2 variants, and for multiple BRCA1/2 variants in tumors harboring a POLE pathogenic variant. Results Four of the five tumors selected because of multiple BRCA1/2 variants exhibited a POLE pathogenic variant, and all three tumors selected for POLE pathogenic variants exhibited multiple BRCA1/2 variants. Conclusions Tumor BRCA testing could be a way to detect tumors harboring a highly mutagenic POLE pathogenic variant.
Collapse
Affiliation(s)
- M-C Villy
- Department of Genetics, Institut Curie, Paris, France
| | - J Masliah-Planchon
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - S Melaabi
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - O Trabelsi Grati
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - E Girard
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - G Bataillon
- Paris Sciences & Lettres Research University, Paris, France.,Department of Pathology, Institut Curie, Paris, France
| | - A Vincent-Salomon
- Paris Sciences & Lettres Research University, Paris, France.,Department of Pathology, Institut Curie, Paris, France
| | - J Le Gall
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - L Golmard
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France
| | - D Stoppa-Lyonnet
- Department of Genetics, Institut Curie, Paris, France.,Université de Paris, Paris, France.,Inserm U830, Institut Curie, Paris, France
| | - I Bieche
- Department of Genetics, Institut Curie, Paris, France.,Université de Paris, Paris, France
| | - C Colas
- Department of Genetics, Institut Curie, Paris, France.,Paris Sciences & Lettres Research University, Paris, France.,Inserm U830, Institut Curie, Paris, France
| |
Collapse
|